This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Edwards Lifesciences Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Announce Investigation Of Possible Breaches Of Fiduciary Duty

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that the firms are investigating legal claims against the officers and Board of Directors of Edwards Lifesciences Corporation (“Edwards Lifesciences” or “Company”) (NYSE:EW) related to potential securities violations between April 25, 2012 and April 23, 2013 (the “Class Period”).

If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at zach@powerstyalor.com. There is no cost or fee to you.

In a recently filed federal class action complaint, Edwards Lifesciences and certain of its officers and directors were charged with violating certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges that defendants’ misrepresented, among other things, that (a) the adoption of SAPIEN was weaker than the Company proclaimed due to concerns among physicians over the risks and complexity of the procedure to implant the valve; (b) the Company’s outlook for sales and earnings per share was significantly weaker than the optimistic guidance Defendants offered to investors; and (c) as a result of the above, the positive statements released by Defendants regarding the Company’s operations, forecasts and outlook were unfounded. According to the complaint, when the truth came out, the share price of Edwards Lifesciences dropped dramatically.

“Recent revelations about alleged improper business practices and procedures regarding key aspects of Edwards Lifesciences’ business and other misleading financial statements have prompted the firms to investigate possible breaches of fiduciary duties and other violations of state law by Edwards Lifesciences’ officers and directors. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of Edwards Lifesciences stock for all shareholders,” said shareholder rights attorney Willie Briscoe.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs